ATE315028T1 - Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester - Google Patents

Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester

Info

Publication number
ATE315028T1
ATE315028T1 AT00310064T AT00310064T ATE315028T1 AT E315028 T1 ATE315028 T1 AT E315028T1 AT 00310064 T AT00310064 T AT 00310064T AT 00310064 T AT00310064 T AT 00310064T AT E315028 T1 ATE315028 T1 AT E315028T1
Authority
AT
Austria
Prior art keywords
trifluoromethyl
methoxycarbonylamino
quinoline
dihydro
benzyl
Prior art date
Application number
AT00310064T
Other languages
German (de)
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE315028T1 publication Critical patent/ATE315028T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00310064T 1999-11-30 2000-11-13 Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester ATE315028T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
ATE315028T1 true ATE315028T1 (de) 2006-02-15

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00310064T ATE315028T1 (de) 1999-11-30 2000-11-13 Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester

Country Status (44)

Country Link
US (1) US6313142B1 (cg-RX-API-DMAC7.html)
EP (1) EP1125929B1 (cg-RX-API-DMAC7.html)
JP (1) JP3579345B2 (cg-RX-API-DMAC7.html)
KR (1) KR100408177B1 (cg-RX-API-DMAC7.html)
CN (1) CN1173953C (cg-RX-API-DMAC7.html)
AP (1) AP2000002011A0 (cg-RX-API-DMAC7.html)
AR (1) AR029775A1 (cg-RX-API-DMAC7.html)
AT (1) ATE315028T1 (cg-RX-API-DMAC7.html)
AU (1) AU784694B2 (cg-RX-API-DMAC7.html)
BG (1) BG105009A (cg-RX-API-DMAC7.html)
BR (1) BR0005636A (cg-RX-API-DMAC7.html)
CA (1) CA2327029C (cg-RX-API-DMAC7.html)
CO (1) CO5261552A1 (cg-RX-API-DMAC7.html)
CY (1) CY1104989T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20004407A3 (cg-RX-API-DMAC7.html)
DE (1) DE60025317T2 (cg-RX-API-DMAC7.html)
DK (1) DK1125929T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3079A1 (cg-RX-API-DMAC7.html)
EA (1) EA003668B1 (cg-RX-API-DMAC7.html)
EE (1) EE200000659A (cg-RX-API-DMAC7.html)
ES (1) ES2254109T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20022798B (cg-RX-API-DMAC7.html)
GT (1) GT200000190A (cg-RX-API-DMAC7.html)
HN (1) HN2000000203A (cg-RX-API-DMAC7.html)
HR (1) HRP20000804A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0004747A3 (cg-RX-API-DMAC7.html)
ID (1) ID28489A (cg-RX-API-DMAC7.html)
IL (1) IL139849A (cg-RX-API-DMAC7.html)
IS (1) IS5715A (cg-RX-API-DMAC7.html)
MA (1) MA25223A1 (cg-RX-API-DMAC7.html)
NO (1) NO20006039L (cg-RX-API-DMAC7.html)
NZ (1) NZ508509A (cg-RX-API-DMAC7.html)
OA (1) OA11494A (cg-RX-API-DMAC7.html)
PA (1) PA8503801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20010913A1 (cg-RX-API-DMAC7.html)
PL (1) PL344208A1 (cg-RX-API-DMAC7.html)
SG (1) SG102603A1 (cg-RX-API-DMAC7.html)
SK (1) SK17792000A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN00230A1 (cg-RX-API-DMAC7.html)
TW (1) TW591016B (cg-RX-API-DMAC7.html)
UA (1) UA65615C2 (cg-RX-API-DMAC7.html)
UY (1) UY26451A1 (cg-RX-API-DMAC7.html)
YU (1) YU71500A (cg-RX-API-DMAC7.html)
ZA (1) ZA200006947B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2003053368A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
EP1492880B1 (en) * 2002-04-11 2008-10-08 Roar Holding LLC Ex vivo method for determination of cetp activity and efficacy of heart disease treatment
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) * 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
BR0317521A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
JP2006523218A (ja) * 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
CA2519458A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
SI1670768T1 (sl) * 2003-10-08 2010-01-29 Lilly Co Eli Spojine in metode za zdravljenje dislipidemije
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
CA2598133A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
EP4551567A1 (en) 2022-07-05 2025-05-14 NewAmsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (cg-RX-API-DMAC7.html) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
CN1173953C (zh) 2004-11-03
GT200000190A (es) 2002-04-27
JP2001163859A (ja) 2001-06-19
PL344208A1 (en) 2001-06-04
HK1038007A1 (en) 2002-03-01
SG102603A1 (en) 2004-03-26
DE60025317T2 (de) 2006-08-03
AP2000002011A0 (en) 2000-12-31
HU0004747D0 (cg-RX-API-DMAC7.html) 2001-02-28
UA65615C2 (uk) 2004-04-15
PE20010913A1 (es) 2001-09-10
EE200000659A (et) 2001-08-15
PA8503801A1 (es) 2002-07-30
NO20006039L (no) 2001-05-31
ES2254109T3 (es) 2006-06-16
HN2000000203A (es) 2001-06-13
CA2327029C (en) 2005-08-09
KR20010052012A (ko) 2001-06-25
CY1104989T1 (el) 2010-03-03
US6313142B1 (en) 2001-11-06
AR029775A1 (es) 2003-07-16
HRP20000804A2 (en) 2001-06-30
CZ20004407A3 (cs) 2002-06-12
OA11494A (en) 2004-05-07
IL139849A0 (en) 2002-02-10
YU71500A (sh) 2003-02-28
TW591016B (en) 2004-06-11
KR100408177B1 (ko) 2003-12-01
EA200001129A2 (ru) 2001-06-25
CO5261552A1 (es) 2003-03-31
UY26451A1 (es) 2001-06-29
ZA200006947B (en) 2002-05-27
DK1125929T3 (da) 2006-04-03
TNSN00230A1 (fr) 2005-11-10
EA200001129A3 (ru) 2001-10-22
DZ3079A1 (fr) 2004-10-24
CA2327029A1 (en) 2001-05-30
SK17792000A3 (sk) 2002-10-08
AU7178900A (en) 2001-05-31
MA25223A1 (fr) 2001-07-02
EP1125929A1 (en) 2001-08-22
NO20006039D0 (no) 2000-11-29
BR0005636A (pt) 2001-07-17
EA003668B1 (ru) 2003-08-28
DE60025317D1 (de) 2006-03-30
BG105009A (en) 2001-11-30
NZ508509A (en) 2001-06-29
HUP0004747A3 (en) 2002-12-28
GEP20022798B (en) 2002-09-25
IS5715A (is) 2001-05-31
CN1302800A (zh) 2001-07-11
EP1125929B1 (en) 2006-01-04
JP3579345B2 (ja) 2004-10-20
HUP0004747A2 (hu) 2001-10-28
ID28489A (id) 2001-05-31
IL139849A (en) 2006-10-31
AU784694B2 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
ATE315028T1 (de) Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester
DE69930317D1 (de) Verfahren zur verhinderung von physiologischen störungen ohne die photosynthese zu vermindern
ATE258927T1 (de) Verbessertes verfahren zur herstellung von n- substituierte aminotetraline
DE60200412D1 (de) Polyhydroxyalkanoat und Verfahren zu dessen Herstellung, und Omega-(2-Thienylsulfanyl)alkansäure und Verfahren zu deren Herstellung
CA2473991A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
NO20035613D0 (no) Fremgangsmåte for naftaavsvovling
DE60010616D1 (de) Wasserdispergierbares Faserflächenprodukt und Verfahren zu seiner Herstellung
DE60035759D1 (de) Gerät für die Plattierung
DE60018531D1 (de) Oxydkomplex als Katalysator und Verfahren für die Herstellung von Acrylsäure
DE60206573D1 (de) Verfahren zum Imprägnieren von Trägern
DE60124296D1 (de) Biphenylcarbonsäureamide, die sich als lipidsenker eignen
DE60017941D1 (de) Benzoesäureester von oxazolidinonen, die hydroxyacetylpiperazin-gruppen tragen
ID24863A (id) Proses pembuatan vinil ester dari butenoligomeran
DE69833200D1 (de) Verfahren für die produktion von l-glutaminsäure mittels fermentation
DE69706903D1 (de) Verfahren für die Herstellung von Mercaptanen
ID28447A (id) Proses polimerisasi kontinu pembuatan poliamida-poliamida dari omega-aminonitril
DE60227857D1 (de) Schuhpressenband und Verfahren zu seiner Herstellung
DE60205502D1 (de) Verfahren zur herstellung von alpha-hydroxycarbonsäureamiden
DE60004072D1 (de) Verfahren für die Herstellung von Lacton
DE60135395D1 (de) Prozess für die Herstellung von (Meth)acrylsäureanhydrid
DE69907865D1 (de) Verfahren zu Herstellung von 3-Alkyl-3-Hydroxymethyloxetanen
DE60201861D1 (de) Stahlherstellungsverfahren
DE60113323D1 (de) Verfahren für die Herstellung von L-Phenylalanin
ATE401299T1 (de) Verfahren für die herstellung von hydroxyethylaminen
DE60010092D1 (de) Verfahren zur herstellung von acylierten 1,3-dicarbonylverbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1125929

Country of ref document: EP

REN Ceased due to non-payment of the annual fee